Compositions and methods for treatment of hepatitis C virus-associated diseases
AssigneeIsis Pharmaceuticals, Inc.
InventorsKevin P. Anderson, Ronnie C. Hanecak, Chikateru Nozaki, F. Andrew Dorr, T. Jesse Kwoh
Life of this patent
Estimating the term…
Abstract
Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
Claims18
An oligonucleotide 5 to 50 nucleotides in length which is complementary to at least a portion of an HCV genomic or messenger RNA, said oligonucleotide being hybridizable to said RNA and capable of inhibiting the function of said RNA.
A phosphorothioate oligodeoxynucleotide having SEQ ID NO:
- 6 wherein every cytidine nucleotide is a 5-methylcytidine.
Dependencies are inferred from the claim text.